In the course of screening using a bleb forming assay1}, we reported the novel inhibitors of protein kinase C (PKC) RK-286C (4'-demethylamino-4'-hydroxystaurosporine)2) and RK-286D3) previously.
Recently, Streptomyces platensis subsp. mahinus RK-1409 was found to produce a new indolocarbazole group antibiotic, RK-1409 shown in Fig. 1 . This compound inhibited PKCin vitro at an extremely low concentration.
In this paper, we describe the fermentation, isolation, physico-chemical properties, and structure elucidation. Details of the taxonomy and the biological activities were described in the preceding paper4).
Experimental

General
MPwas measured with a Yanaco micro melting point apparatus. Optical rotation was measured by a Perkin-Elmer 24IMCpolarimeter. UVand IR spectra were taken on a Hitachi 220A spectrometer and a Shimadzu IR27G recording IR spectrometer, respectively. EI-MS spectra were obtained with a Hitachi M-80 mass spectrometer. *H NMRspectra were recorded on a Jeol GSX-500spectrometer. Fermentation Strevtomvces vlatensis subsp. malvinus RK-1409was cultured in a 500-ml cylindrical flask containing 70ml of seed medium (glucose 2%, soluble starch 1%, soybean meal 2.5%, meat extract 0.1%, dried yeast 0.4% and NaCl 0.2%, adjusted to pH 7.0). The fermentation was carried out on a rotary shaker (250 rpm) at 28°C for 72 hours. The seed culture was transferred to a 30-liter jar fermenter containing 18 liters of the same medium. The fermentation was carried out at 28°C with aeration of 13 liters/minute and agitation of 350rpm for 72 hours.
Isolation and Purification
Culture broth (18 liters) was filtered and the mycelium was extracted with 10 liters acetone. The Oxidation of Staurosporine A solution of( + )-staurosporine (35 mg), 70% tert-buty\ hydroperoxide (1 ml), Mn(III)acetylacetonate (2.64mg) and EtOAc (1 ml) was stirred at 4°C. After stirring for 2 days Mn(III)acetylacetonate (2.64mg) and EtOAc (0.5 ml) were added to the solution, and stirred further for 2 days at 4°C. The reaction mixture was subjected to silica gel (3.0 g) column chromatography eluted with EtOAc 15 ml and subsequently 10% MeOH-CHCl3 10ml. The fraction of 10% MeOH-CHCl3 was concentrated in vacuo and purified by HPLC.7-Oxostaurosporine purified was 1.5mg and staurosporine recovered was 5.0mg. Synthetic 7-oxostaurosporine; MP >230°C (dec), [a]£2 +36.9°(c 0.29, CHC13). Other spectral data and retention time on HPLCanalysis were completely identical with natural RK-1409. 
Results and Discussion
Structure
The UV spectrum of RK-1409 suggested the presence of an indolo [2,3a] pyrrolo [3,4c] carbazole-5,7(67f)-dione system as chromophore6'7). The *H NMRdata of RK-1409 and staurosporine are summarized in Table 1 . Comparison of the spectral data and decoupling experiments revealed the presence of two 1,2-disubstituted benzene rings and the same sugar moiety as that of staurosporine. The absence of the signal of the 7-H methylene protons and the chemical shift of a second deshielded aromatic proton at 3 9.35 ppm 8-H indicated the presence ofa carbonyl group at C-7. These data suggested that the structure of RK-1409was 7-oxostaurosporine. Oxidation of (+)-staurosporine with tert-buty\ hydroperoxide and Mn(III)acetylacetonate8) gave 7-oxostaurosporine. Spectral data of this oxidative product were identical with natural RK-1409. This oxidation confirmed the proposed structure ofRK-1409, with the same absolute stereochemistry as that of staurosporine9).
The structure of RK-1409 is a hybrid of a staurosporine type sugar moiety9~11} and a 7-oxo-type indolocarbazole chromophorewhichis similar to the aglycone of the antitumor antibiotics rebeccamycin6' 1 2) and AT24337 '13) . Therefore the biological activity of this novel antibiotic RK-1409 is interesting from the viewpoint of structure-activity relationships. Details of the inhibitory activities against someprotein kinases were described in the preceding paper4) and elsewhere.
After a preliminary report of these results14) and the submission of this paper, we found that 7-oxostaurosporine was reported as an antitumor antibiotic BMY-41950by Bristol-Myers Squibb Co.
and an oxidative derivative of staurosporine by KyowaHakko Kogyo Co., Ltd. in patents15 '16) .
